Response to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione S-transferases. by Peters, W. H. et al.
Br. J. Cancer (1993), 68, 86-92 © Macmillan Press Ltd., 1993~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Response to adjuvant chemotherapy in primary breast cancer: no
correlation with expression of glutathione S-transferases
W.H.M. Peters', H.M.J. Roelofs', W.L.J. van Putten2, J.B.M.J. Jansen', J.G.M. Klijn3 &
J.A. Foekens3
'Department ofGastroenterology, St Radboud University Hospital, PO Box 9101, 6500 HB Nijmegen, and 'Department of
Statistics and 'Division ofEndocrine Oncology (Department ofMedical Oncology), Dr Daniel den Hoed Cancer Center, PO Box
5201, 3008 AE Rotterdam, The Netherlands.
Summary Of 139 node-positive breast cancer patients treated with adjuvant chemotherapy, the pre-treatment
levels of glutathione S-transferase (GST) classes alpha, mu and pi, were determined by immuno-quantification
on Western blots in cytosols of the primary tumours. Their expression was studied with respect to cytosolic
oestrogen-receptor, progesterone-receptor and cathepsin D levels, and to the length of disease-free survival.
GST class pi was negatively correlated with oestrogen receptor and progesterone receptor, and positively
correlated with cathepsin D. There was no correlation between GST isoenzymes and the length of disease-free
survival. These data suggest that glutathione S-transferases are not useful as markers to predict the response to
adjuvant chemotherapy in human breast cancer.
Resistance to chemotherapy is a common clinical problem in
the treatment of cancer. To achieve a more effective
chemotherapeutic treatment of breast cancer patients in the
future, it is essential to establish which mechanisms are re-
sponsible for drug resistance, and in addition, to define
reliable indicators of response to treatment in individual
patients. A wide variety of mechanisms have been implicated
in the aetiology of resistance to cytotoxic drugs (Harris,
1990), including the action of detoxifying enzymes such as
glutathione S-transferases (Waxman, 1990; Tsuchida & Sato,
1992). This family of enzymes is involved in the biotransfor-
mation of a wide variety of compounds, including several
chemotherapeutic drugs (Dulik et al., 1986; Wolf et al., 1986;
Cazenave et al., 1989; Bolton et al., 1991; Ciaccio et al.,
1991; Yuan et al., 1991). Glutathione S-transferases are
divided into three classes of enzymes called alpha, mu and pi,
each consisting of several isoenzymes (Mannervik & Daniel-
son, 1988; Vos & van Bladeren, 1990).
Class pi and mu glutathione S-transferases are expressed in
the majority of both normal and tumourous breast tissue
whereas class alpha enzymes are absent or hardly detectable
in the majority of specimens (Howie et al., 1989 and 1990;
Forrester et al., 1990; Shea et al., 1990; Terrier et al., 1990;
Campbell et al., 1991; Kantor et al., 1991).
In primary breast tumours the level of glutathione S-
transferase pi was found to be inversely related with the level
of oestrogen receptor (ER) (Moscow et al., 1988), and in
breast tumour cells in vitro overexpression of class pi
glutathione S-transferase has been implicated with multidrug
resistance (Cowan et al., 1986).
Cathepsin D, an enzyme generally overexpressed in breast
cancer cells under oestrogen stimulation in ER-positive cells
and constitutively overexpressed in ER-negative cells, has
been shown to be associated with increased risk of develop-
ing metastasis (Rochefort, 1992). Moreover, cathepsin D
might be associated with chemoresistance (Namer et al.,
1991), but no relationships with glutathione S-transferases
have yet been reported in the literature.
In the present study we examined the relationships between
the pre-treatment glutathione S-transferase class alpha, mu
and pi levels in primary breast tumours and patient and
tumour characteristics, including steroid-receptor and cathep-
sin D status, and the length of disease-free survival following
adjuvant chemotherapy.
Patients and methods
Patients and tumour samples
Tumour specimens from 139 patients (mean age, 45.5 years)
with positive regional lymph nodes but with no signs of
distant metastasis, who underwent surgery for primary breast
cancer (modified mastectomy, 78 patients; breast conserving
lumpectomy, 54 patients; biopsy only, seven patients), were
included in this study. Selection for this study was made on
the basis of the following criteria: primary tumour tissue
must be available in the tumour bank (liquid nitrogen),
patients must have undergone primary surgery or been refer-
red to the Dr Daniel den Hoed Cancer Center for (adjuvant)
radiotherapy between 1978 and 1987, patients must have
received adjuvant chemotherapy, and clinical information of
status at presentation and follow-up must be available. Of
these patients, 118 were pre/perimenopausal and 21 were
postmenopausal, defined as described previously (Foekens et
al., 1989a). In the Dr Daniel den Hoed Cancer Center,
patients under 56 years of age received 6 cycles of adjuvant
standard combination chemotherapy (cyclophosphamide,
methotrexate, 5-fuorouracil; classical CMF). Of 21 post-
menopausal patients, only 7 were over 56 years of age and
were treated elsewhere. Patients were routinely examined
every 3 to 6 months during the first 5 years and once a year
thereafter (median follow-up, 48.3 months; range, 28-128
months). Of the 139 patients included in this study, 39 have
died. Sixty-eight patients showed evidence of recurrence dur-
ing follow-up, and count as failures in analysis for disease-
free survival.
Oestrogen receptor (ER), progesterone receptor (PgR) and
cathepsin D assays
Tissue was pulverised in the frozen state, homogenised, and
cytosolic ER and PgR levels were determined with radioli-
gand binding assays as recommended by the EORTC Recep-
tor Study Group (EORTC Breast Cancer Cooperative
Group, 1980), and as described before (Foekens et al.,
1989b). Cathepsin D was measured by radiometric
immunoassay kits (ELSA-CATH-D; kindly provided by Dr
B. Thirion, CIS bio International. Gif-sur-Yvette, France).
Quantification ofglutathione S-transferases class alpha, mu
andpi
Cytosolic fractions of tumour tissue were subjected to SDS
polyacrylamide gel electrophoresis and subsequently to
Western blotting as described before (Peters et al., 1992).
Western blots were incubated with monoclonal antibodies
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against glutathione S-transferase class alpha (Peters et al.,
1992), class mu (Peters et al., 1990a) and class pi (Peters et
al., 1989). The specific binding of the monoclonal antibodies
to their antigens was determined as previously described
(Peters and Jansen, 1988). Staining intensity was quantified
by densitometry (Ultroscan XL, LKB, Bromma, Sweden)
using purified glutathione S-transferases as marker proteins
(see legend of Figure 1). The detection limit of the method
described above is approximately 40 ngmg' protein. Class
pi glutathione S-transferase was quantified in tumour samples
from all 139 patients. Due to limited amounts of protein,
glutathione S-transferase class mu and alpha were analysed
in 138 and 132 patient samples, respectively.
Statistics
Associations between glutathione S-transferases and patient
and tumour characteristics were studied with Spearman rank
correlations and with cross-tabulations after division of the
range of values of the GST parameters in two or three
classes. The division in two or three classes was done in order
to study the possibility of a trend and to visualise this with
survival curves. The Kurskal Wallis test was used to test for
differences in the distribution of GST values in different
classes defined by patient and tumour characteristics.
Disease-free and overall survival probabilities were calculated
by the actuarial method of Kaplan and Meier. The univariate
Cox regression model was used to test for differences and
trend.
Results
Incidence ofpositivity and levels ofglutathione S-transferases
Cytosolic protein levels of glutathione S-transferases class
alpha, mu and pi were determined after immunodetection
with monoclonal antibodies on Western blots. Examples of
the respective immunoblots are shown in Figure 1. Class
alpha GST was detectable in 28 of 132 tumours (21%)
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Figure 1 Immunodetection of glutathione S-transferase alpha, mu and pi in breast tumours. Cytosolic samples (33fig protein)
were subjected to SDS polyacrylamide gelelectrophoresis (11% acrylamide; w/v) and Western blotting. The Western blots were
incubated with monoclonal antibodies against class alpha (upper panel), class mu (middle panel) and class pi glutathione
S-transferase (lower panel). The higher molecular weight mass band (middle panel) represents class mu glutathione S-transferase,
while the origin of the lower molecular mass band is unknown. Samples from patients # 1-16 are shown here. Lane m contains
purified glutathione S-transferase alpha (upper panel; 155 ng protein), mu (middle panel; 137 ng protein) and pi (lower panel;
193 ng protein) respectively.88 W.H.M. PETERS
examined, GST-mu in 83 of 138 tumours (60%), and GST-pi
in 136 of 139 cytosols (98%) analysed. The distributions of
the concentrations of the GST subclasses are shown in
Figure 2. The levels of GST-alpha ranged from 0 to
1.12i.gmg-' protein (mean ± s.d., 0.04 ± 0.141tgmg'
I pro-
tein). The median levels of GST-pi and GST-mu were 1.38
(range, 0-13.4; mean ± s.d., 2.0 ± 2.1)jg mg' protein and
0.32 (range, 0-5.3; mean + s.d., 0.8 ± 1.1) ygmg'I protein,
respectively (medians are indicated by arrows in Figure 2).
The associations between the levels of GST-alpha with
those of GST-mu and GST-pi are shown in Table I.
Tumours were classified as negative (below detection limit) or
positive for GST-alpha. Regarding GST-mu, tumours were
divided into three groups, i.e. one group negative for GST-
mu and two groups containing detectable levels of GST-mu
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Table I Associations of GST-alpha with GST-mu and GST-pi
GST-alpha
(number ofpatients)
Negative Positivea (%) Total
GST_mub
Negative 42 10 (21) 52
Low 32 9 (22) 41
High 30 9 (23) 39
GST-pic
Low 39 10 (20) 49
Medium 34 6 (15) 40
High 31 12 (28) 43
Total 104 28 (21) 132
'Positive: above detection limit. bGST-mu: low, 0.03-1.08; high,
> 1.08 tLg mg' protein. cGST-pi: low, <0.8; medium, 0.8-2.5;
high, >2.5gsg mg-' protein.
such that an approximately equal number of patients was
a present in each group. Similarly, tumours containing different
amounts ofGST-pi were divided into three groups, based on
the concentration of GST-pi. No significant associations of
GST-alpha with either GST-mu or GST-pi were noticed. The
absence of a significant association between the levels of mu
and pi classes of GST (Spearman correlation coefficient,
Rs = 0.09) is visualised by the scatterplot shown in Figure
3.
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Figure 2 Distribution of glutathione S-transferase class alpha a,
mu b, and pi c over human primary breast tumour cytosols.
Arrows indicate median values.
Glutathione S-transferases andpatient and tumour
characteristics
The associations of the levels of GST-alpha, GST-mu or
GST-pi, with age and menopausal status of the patients,
tumour size, the number of positive lymph nodes, and with
cytosolic ER, PgR and cathespin D, are shown in Table II.
Although no statistically significant associations (Kruskal-
Wallis test) of any of the three subclasses of GST with
clinical parameters were observed, GST-alpha was more
often not detectable in small tumours, i.e. TI-tumours were
positive for GST-alpha in only four out of 46 cases (9%), as
compared with 17 out of 55 (31%) T2-tumours and with
seven out of 28 (25%) T3/T4-tumours. Regarding an associa-
tion between GST and other cytosolic factors, the highest
GST-pi levels were found more frequently in ER-negative
(P = 0.05) and PgR-negative tumours (P<0.03), and in
tumours with high cathepsin D concentrations, although in
the latter case this association was not statistically significant.
Ofthe ER-negative or PgR-negative tumours, 47% contained
high GST-pi concentrations as compared with 26% of ER-
positive or PgR-positive tumours (Table II). The associations
between GST-pi and ER, PgR and cathepsin D, are
visualised by scatterplots in Figure 4. A very weak negative
relationship between GST-pi and ER (Spearman correlation
coefficient: Rs = -0.17, 2P<0.05) and PgR (Rs = -0.13,
N.S.) levels, and in addition a very weak positive relationship
between GST-pi and cathepsin D (Rs = +0.17, 2P<0.05)
levels were observed. GST-mu and GST-alpha concentrations
were not significantly related with those of ER, PgR or
cathepsin D.
Glutathione S-transferases and (disease-free) survival
The levels of none of the three classes of glutathione S-
transferase studied appeared to be associated with the length
of disease-free survival after the administration of adjuvant
chemotherapy, as is shown by Kaplan-Meier curves in Figure
5. Univariate P-values in Cox univariate regression analyses
were 0.27, 0.24, and 0.72, respectively, for GST-alpha, -mu
and -pi. Also in Cox regression analyses for overall survival,
none of the GST's studied was associated with the rate of
death (P-values ranging from 0.42 to 0.63).
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Figure 3 Scatterplot of individual values of glutathione S-transferase mu vs. glutathione S-transferase pi in breast tumour cytosols.
Rs: Spearman rank correlation.
Table II Associations of GST levels with patient and tumour characteristics
GST-alphaa GST-mua GST-pF
Characteristic Neg Pos Neg Low High Low Medium High
Number of patientsb 104 28 55 42 41 51 44 44
Age
<43 yr 40 10 22 14 15 15 18 18
44-50 yr 38 14 20 18 16 20 17 17
> 51 yr 26 4 13 10 10 16 9 9
Postmenopausal
Yes 15 3 7 8 5 11 5 5
No 89 25 48 34 36 40 39 39
Tumour size
T1 ( <2cm) 42 4 18 15 14 15 19 13
T2 (2-5cm) 38 17 21 16 21 20 15 24
T3 (>5cm) 14 4 10 7 2 8 7 4
T4 7 3 6 3 3 7 2 2
Lymph nodes
1-3 65 15 34 23 26 30 28 26
> 3 38 13 19 19 15 20 15 18
ERC
Neg 27 6 15 14 6 8 11 17
Pos 77 22 40 28 35 43 33 27
PgRc
Neg 23 12 12 17 6 9 10 17
Pos 77 16 39 25 34 41 32 25
Cath-Dd
Low 50 17 27 21 21 29 21 18
High 54 11 28 21 20 20 22 26
aDefinition of neg, pos, low and high, are as defined in the legend to Table I.
bNumber ofpatients per group (due to missing values they do not all add up to 139).
cNeg, <10; pos, > 10 fmolmg' protein. 4Low, <45; high, >45 pmol mg-
protein.
Discussion
Adjuvant chemotherapy is a widely used systemic treatment
for breast cancer patients after surgical removal of the
tumour. However, in the vast majority of the cases resistance
to this therapy develops in the treatment of metastatic
disease. Understanding of the mechanism underlying this
resistance should lead to future improvements of therapeutic
results. A wide variety of factors may be involved in resis-
tance to chemotherapeutics of breast tumours, and recent
evidence suggests that glutathione S-transferase pi may be of
relevance (Cowan et al., 1986; Moscow et al., 1988). Having
studied specimens from 21 breast cancer patients, Moscow et
al. reported an inverse relationship between glutathione S-
transferase pi levels and oestrogen receptor content, a finding
which was confirmed by Howie et al. (1989) in 58 patients,
but not by Shea et al. (1990), who investigated 45 tumour
samples. In this study involving 139 different tumour sam-
ples, also a weak but statistically significant inverse correla-
tion between GST-pi and ER was found. In addition, we
observed a weak inverse correlation between GST-pi and
PgR, and a weak positive correlation between GST-pi and
cathepsin D.
Class mu glutathione S-transferase deficiency, occurring in
10- 0 0
0
0
0
0
0
8
0 0
0)
E
CD
._
cn
0
0
0
0
0
0
8 0.1I
0
0
0
0
0
0
0
iI . 1
0.1 10
,, o
190 W.H.M. PETERS
a 1.OF
a
<,; ---, ~~~GST-alpha
. ,~~~~--
X ~ ~ ~ ~ ~ ~~ ---I
AL , ~ ~ ~ ~ ~ ~ ~
0.81
o o a o o~~~~o o. 0 0 Co °00 ° o e
o0 0 0 o
0 0 0 0 000 0000 .8 00
0 0 0 0 0 0
0o 0
0
0.6[
0.41
0.2 -
10 100 1000
ER [fmol mg-1 protein]
Rs = -0.13
1.'O
b
0 0 a0
0
00 0
o 8
0 0:D 000D
:.0 ~~~~0 0
00 0 0 0
0
I .
10 100
PgR [fmol mg-1 protein]
U)
a) 2
CA
a)
U)
4)
U) co
4)
._
co .0
20
1000
12 24 36 48 60
b
0.8
*--^ GST-mu
_- _
'-----!-_--.
0.61
0.41
0.2 _
I
D 12 24 36 48 60
, -,, GST-pi
. _
_~~~~~~~t -,
I ,
|~~~~~~~~~~~
100'
c
._
4-0
0
10
0)
E
1'
.a
1- 0.1
<0.02
Rs= +0.17 C
00 00 O
0 0 000 o00 0
0
0 0 40 o cO;o
0
<5 10 100 000o
Cathepsin D [pmol mg-1 protein]
Figure 4 Scatterplots of associations of glutathione S-transferase
pi with ER a, PgR b and cathepsin D c. Rs: Spearman rank
correlation.
approximately 40% of a normal Caucasian population has
been implicated with an increased risk for developing lung
carcinomas in smokers (Seidegard et al., 1990). In addition,
increased cytogenetic damage was observed in in vitro studies
with glutathione S-transferase mu deficient human blood cells
(Wiencke et al., 1990; van Poppel et al., 1992). Our results
demonstrate that 40% of the 138 breast cancer samples
investigated are negative for the mu class enzymes. So in
accordance with an earlier study involving a different group
of 52 breast cancer patients (Peters et al., 1990a) this more
extensively study leads to the same conclusion that gluta-
thione S-transferase mu deficiency does not occur more often
in breast cancer patients and therefore class mu deficiency
seems not to be involved in the aetiology of breast
cancer.
The disease-free survival curves for our patient group
treated with adjuvant chemotherapy show an equal relapse
pattern for tumours with a high or low content of
glutathione S-transferase alpha, mu or pi. Therefore these
glutathione S-transferases are not useful as predictive
0.2
0 12 24 36 48 60
Months
Figure 5 Probability disease-free survival curves stratified by
glutathione S-transferase class alpha a, mu b and pi status c. a,
negative (53/104), positive (11/28); b: negative
24/55), --- low (22/42), - high (20/41); c: low (24/51),
--- medium (22/44), - high (19/44). Numbers between paren-
theses represent failures (occurring in the first 60 months)/total
number of patients in each group. Negative, low, medium and
high for glutathione S-transferase mu or pi are as defined in the
legend to Table I.
markers for patients to be treated with adjuvant
chemotherapy. Adjuvant chemotherapy with CMF is
especially effective in premenopausal patients but also
significantly in the age group of 50-60 years-old (Early
Breast Cancer Trialists' Collaborative Group, 1992), to which
category a small minority of our patients belong. The higher
efficacy in younger patients compared to patients over 60
years of age is possibly related to an endocrine mechanism of
action, namely chemical castration. Whether the glutathione
S-transferases are relevant in patients receiving hormonal
therapy or no treatment needs to be investigated. In a very
preliminary study on 34 patients with ER-positive locally
advanced breast cancer, Dorian-Bonnet et al. (1992) found
that 12 patients with an objective response to tamoxifen
showed significant lower GST-pi levels in their tumour than
the other non-responding patients. Our results are in good
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agreement with a recent study in 68 patients with advanced
breast cancer receiving mitozantrone therapy. In this study of
Wright et al. (1992), using an immunohistochemical method
to assess GST status, no correlation between glutathione
S-transferase alpha, mu or pi content of the primary tumour
and the response rate or duration of response could be
detected. Also in an in vitro chemosensitivity study on
primary breast cancer tissue from untreated patients, no
correlation between drug (doxorubicin) sensitivity and
glutathione S-transferase (pi) was observed (Keith et al.,
1990). For patients with ovarian cancer, large changes in
glutathione S-transferase enzyme activity or isoenzyme
(alpha, mu and pi) expression were not likely to be a major
determinant of resistance to chemotherapy (Murphy et al.,
1992). In addition, a lack of a role of glutathione S-
transferase pi in drug resistance of malignant ovarian
tumours to platinum/cyclophosphamide chemotherapy has
recently been reported (van der Zee et al., 1992).
In contrast to many other tumour types such as tumours
from the lung (Howie et al., 1990), stomach (Peters et al.,
1990b), colon (Peters et al., 1992), or ovary (Murphy et al.,
1992), breast tumours do not express higher levels of
glutathione S-transferases as compared to their correspond-
ing normal tissues (Howie et al., 1990: Tsuchida & Sato,
1992). Thus the transformed breast cell in this respect is
similar to the normal breast cell which also argues against a
role for glutathione S-transferase with respect to malignant
transformation and drug resistance of the breast (tumour)
cells.
In conclusion, the lack of an association of glutathione
S-transferases with the length of disease-free survival follow-
ing adjuvant CMF chemotherapy of patients with primary
breast cancer, suggests that these detoxifying enzymes are not
useful in selecting patients who may benefit from adjuvant
CMF chemotherapy. In view of the fact that no control
group was included in this study, a possible prognostic (in-
stead of predictive) value of glutathione S-transferases in an
untreated patient population cannot totally be excluded.
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